Compound or practice · Supplement

Strontium

A bone-density mineral where the prescription form worked but raised cardiovascular risk — the OTC citrate is a different, unproven story.

Overall grade
Grade C
Last revised
2
graded outcomes
0
references listed

A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.

1 at grade B · 1 at grade D — 2 graded rows

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

  • Fracture (ranelate, Rx)Evidence grade B

    But CV risk

    Moderatehigh

  • Bone (citrate supplement)Evidence grade D

    No fracture data

    Unclearlow

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

  • Thin evidence: Bone (citrate supplement) (grade D).
  • Watch with Calcium: Competes with calcium absorption — separate them.

Interactions

Documented pairings with supplements and medicines. A medicine on this list is a conversation for whoever prescribes it.

  • CalciumMind the timing

    Competes with calcium absorption — separate them.

The evidence in words

What it is

Strontium is a mineral chemically similar to calcium; the drug strontium ranelate was used for osteoporosis, while supplements use strontium citrate.

How it works

It incorporates into bone and appears to both increase formation and reduce resorption; it also inflates DXA bone-density readings (a measurement artifact).

What the evidence shows

Prescription strontium ranelate reduced fractures but was restricted over heart-attack and clot risk. The OTC citrate form lacks fracture-outcome trials, and the density gains partly reflect a scan artifact, not new bone.

Safety & interactions

Cardiovascular-risk signal (from the ranelate data); interferes with calcium absorption and DXA interpretation. Calcium — Competes with calcium absorption — separate them.

Bottom line

The effective form carried cardiovascular risk and was restricted; the supplement form is unproven and confounds bone scans. Not a first-line bone choice.

Entries that share this one's tags or conditions.

Sources

This entry lists no references of its own.

Last revised . A grade is this entry's reading of the evidence, not medical advice.